Syphilis is one of the vital sexually transmitted infections (STIs) caused by the bacteria named, Treponema pallidum, and can lead to long-term complications, if not diagnosed adequately. Syphilis continues to be a global health concern due to the increasing incidences occurring mainly among bisexuals, gays and MSM (men who have sex with men). According to the World Health Organization (WHO), there were an estimated 36 million cases of syphilis in 2013 globally, with over 11 million new cases occurring annually. Additionally, around 90% of the syphilis cases are prevalent in developing countries with similar trends now observed in developed nations as well. The increasing syphilis cases are mainly due to the growing rate of anonymous sex, sex with multiple partners, sex under the influence of several drugs and increasing number of unprotected sex both anal and oral. Moreover, this is also gaining prominence in pregnant women due to the sex with infected partners, which can further lead to congenital abnormalities such as stillbirth, abortions and other abnormalities in pregnancy.
The global syphilis testing market is expected to reach $3,650.3 million by 2020, at a CAGR of 1.2%, from 2014 to 2020. There are various methods used for diagnosing syphilis cases, which include venereal disease research laboratory (VDRL) test, rapid plasma reagin (RPR) test, enzyme immunoassay (EIA) test and few others. All syphilis tests are serological i.e. based upon antibodies present in the body fluid. The market would continue to grow primarily due to the rising incidences of fatal syphilis diseases, disease-related high-economic burden and concurrent implementation of new programs such as provider-initiated counselling and testing (PICT) and client-initiated counselling and testing (CICT). However, inadequate infrastructure provisions such as labs, equipment and supplies, lack of trained laboratory personnel in secluded geographic locations such as West African countries and the stigma associated with voluntary testing are likely to be some of the major restraints of the market.
The report segments the global syphilis testing market on the basis of type and geography. Based on type, the market is segment into primary and secondary syphilis testing. Geographically, the market is segmented into North America, Europe, Asia Pacific and LAMEA. LAMEA and Asia Pacific region account for majority of the syphilis testing market and collectively accounted for 4/5th share of the global market value in 2014. Higher adoption rates for technologically advanced screening tests, active measures from the governments and private associations along with the growing awareness for the syphilis infections largely contribute to growth of the market in the aforesaid regions. The major players in the syphilis testing market are focusing on technological advancements in developing syphilis testing products along with complementary service portfolios. Some of the key companies profiled in the report are Roche Diagnostics, Hologic, Inc., Becton Dickinson & Company, Abbott Laboratories, BioMerieux, Alere Inc., Cepheid Inc., Affymetrix, Inc. and Diasorin.
KEY MARKET BENEFITS:
This report provides an extensive analysis of the current and emerging market trends along with the market dynamics of the global Syphilis testing market
A comprehensive analysis of types and geography segments helps to identify the growth opportunities in the global syphilis testing market
Competitive intelligence (of leading manufacturers and distributors of leading syphilis testing devices and services) highlights the business practices followed by leading market players across the geographies
The projections in the report are made by analyzing the current market trends and market potential for the period of 2014-2020, in terms of value and volume
SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
KEY MARKET SEGMENTS:
The global syphilis testing market is segmented into types and geography.
The Global Syphilis Testing Market – By Types
Primary Syphilis
Secondary Syphilis
The Global Syphilis Testing Market – By Geography
North America
United States
Canada
Mexico
Europe
U.K.
Germany
Spain
Greece
Belgium
Moldova
Rest of Europe
Asia-Pacific
Australia
Japan
India
China
Rest of Asia Pacific
LAMEA
Latin America
Middle East
Africa
Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.1 Research methodology
1.1.1 Secondary research
1.1.2 Primary research
1.1.3 Analyst tools and models
Chapter: 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
Chapter: 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Upcoming trends for Syphilis diagnostic testing market
3.2.1 Executing and ensuring accreditation for the qualification of participants in National Screening Programs around the globe.
3.2.2 Technological Advancements for Syphilis diagnostic testing market
3.3 Syphilis diagnostic tests
3.4 Key Findings
3.4.1 Top Factors Impacting global Syphilis diagnostic testing market
3.4.2 Top Investment Pockets of global Syphilis diagnostic testing market (2014-2020)
3.4.3 Top winning strategies of global Syphilis diagnostic testing market
3.5 Government Regulations and reimbursement scenario
3.5.1 Government Regulation
3.5.2 Reimbursement policies for Syphilis testing
3.6 Value Chain Analysis
3.6.1 Primary Activities
3.6.2 Supportive Activities
3.7 Market dynamics
3.7.1 Drivers
3.7.1.1 Growing incidence rates and increasing prevalence rates of Syphilis
3.7.1.2 Implementation of National Screening Programs
3.7.1.3 Supporting Reimbursement for Syphilis testing
3.7.2 Restraints
3.7.2.1 Social stigma associated with patients visiting specialized STD clinics.
3.7.2.2 Huge proportion of patients infected with Syphilis in remote areas.
3.7.2.3 Stringent regulatory abidance requirements for the participants of Syphilis market
3.7.3 Opportunities
3.7.3.1 Decreasing number of visits to GUM clinics and specialized STD clinics
3.7.3.2 National screening Programs across the globe
3.7.3.3 Niche opportunities for technology and POC test providers in an emerging economies
Chapter: 4 GLOBAL SYPHILIS TESTING MARKET, BY TYPE, 2014-2020
4.1 P&S Syphilis testing (volume and value)
4.1.1 Key market trends
4.1.2 Market size and forecast, (volume & value)
4.1.2.1 Global Testing Market for Syphilis,value, ($million)
4.1.2.2 Global Testing Market for Syphilis, volume, (million)
4.2 Primary Syphilis
4.3 Secondary Syphilis
4.3.1 Market size and forecast, (volume & value)
Chapter: 5 GLOBAL SYPHILIS TESTING MARKET, BY GEOGRAPHY, 2014-2020
5.1 North America
5.1.1 Market size and forecast, (volume & value)
5.1.2 U.S.
5.1.2.1 Market size and forecast (Volume & Value)
5.1.3 Mexico
5.1.3.1 Market size and forecast, (volume & value)
5.1.4 Canada
5.1.4.1 Market size and forecast, (volume & value)
5.2 Europe
5.2.1 Market size and forecast, (volume & value)
5.2.2 Spain
5.2.2.1 Market size and forecast, (volume & value)
5.2.3 Greece
5.2.3.1 Market size and forecast, (volume & value)
5.2.4 Belgium
5.2.4.1 Market size and forecast, (volume & value)
5.2.5 Germany
5.2.5.1 Market size and forecast, (volume & value)
5.2.6 Moldova
5.2.6.1 Market size and forecast, (volume & value)
5.2.7 United Kingdom
5.2.7.1 Market size and forecast, (volume & value)
5.2.8 Rest of Europe
5.2.8.1 Market size and forecast, (volume & value)
5.3 Asia Pacific
5.3.1 Market size and forecast, (volume & value)
5.3.2 India
5.3.2.1 Market size and forecast, (volume & value)
5.3.3 China
5.3.3.1 Market size and forecast, (volume & value)
5.3.4 Japan
5.3.4.1 Market size and forecast, (volume & value)
5.3.5 Australia
5.3.5.1 Market size and forecast, (volume & value)
5.3.6 Rest of Asia-Pacific
5.3.6.1 Market size and forecast, (volume & value)
5.4 LAMEA
5.4.1 Market size and forecast, (volume & value)
5.4.2 Latin America
5.4.2.1 Market size and forecast, (volume & value)
5.4.2.2 Argentina
5.4.2.2.1 MARKET SIZE AND FORECAST, (VOLUME & VALUE)
5.4.3 Middle East
5.4.3.1 Market size and forecast, (volume & value)
5.4.4 Africa
5.4.4.1 Market size and forecast, (volume & value)
Chapter: 6 COMPANY PROFILES
6.1 Roche Diagnostics
6.1.1 Company overview
6.1.2 Roche Diagnostics company snapshot
6.1.3 Operating business segments
6.1.4 Financial performance
6.1.5 Strategic moves and developments
6.1.6 SWOT analysis Roche Diagnostics
6.2 BioMerieux
6.2.1 Company overview
6.2.2 Biomerieux Company Snapshot
6.2.3 Operating business segments
6.2.4 Business performance
6.2.5 SWOT analysis of BioMerieux
6.3 Hologic, Inc.
6.3.1 Company overview
6.3.2 Hologic, Inc. Company Snapshot
6.3.3 Operating business segments
6.3.4 Financial performance
6.3.5 Strategic moves and developments
6.3.6 SWOT analysis of Hologic Inc
6.4 Becton Dickinson And Company
6.4.1 Company overview
6.4.2 Becton Dickinson And Company Snapshot
6.4.3 Operating Business Segments
6.4.4 Business performance
6.4.5 Key Strategies and development
6.4.6 SWOT analysis of Becton Dickinson and Company
6.5 Cepheid Inc.
6.5.1 Company overview
6.5.2 Cephide Inc. company snapshot
6.5.3 Operating Business Segments
6.5.4 Financial performance
6.5.5 Strategic moves and developments
6.5.6 SWOT analysis of Cepheid Inc.
6.6 Danaher Corporation
6.6.1 Company overview
6.6.2 Danaher Corporation Company Snapshot
6.6.3 Operating business segments
6.6.4 Business performance
6.6.5 Key Strategies and development
6.6.6 SWOT analysis of Danaher Corporation
6.7 Affymetrix, Inc.
6.7.1 Company overview
6.7.2 Affymetrix Inc. Company Snapshot
6.7.3 Operating. business segments
6.7.4 Financial performance
6.7.5 SWOT analysis of Affymetrix Inc
6.8 Alere Inc.
6.8.1 Company overview
6.8.2 Alere Inc. Company Snapshot
6.8.3 Operating business segments
6.8.4 Business performance
6.8.5 Key Strategies and developments
6.8.6 SWOT analysis of Alere Inc.
6.9 Abbott Laboratories
6.9.1 Company overview
6.9.2 Abbott Laboratories company snapshot
6.9.3 Operating business segments
6.9.4 Financial performance
6.9.5 Strategic moves and developments
6.9.6 SWOT analysis of Abbott Laboratories
6.10 DiaSorin
6.10.1 Company overview
6.10.2 DiaSorin Company Snapshot
6.10.3 Operating business segments
6.10.4 Financial performance
6.10.5 Strategic moves and developments
6.10.6 SWOT analysis of DiaSorin
LIST OF FIGURES
FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
FIG. 2 IMFPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
FIG. 4 TOP FACTORS IMPACTING GLOBAL SYPHILIS TESTING MARKET, 2014-2020
FIG. 5 TOP INVESTMENT POCKETS OF GLOBAL SYPHILIS TESTING MARKET (2014-2020)
FIG. 6 TOP WINING STRATEGIES IN GLOBAL SYPHILIS TESTING MARKET (2011-2014)
FIG. 7 VALUE CHAIN ANALYSIS OF GLOBAL SYPHILIS TESTING MARKET
FIG. 8 SYPHILIS INCIDENCE IN MEXICO (2009-2013)
FIG. 9 SYPHILIS INCIDENCE RATE IN MEXICO (2009-2013)
FIG. 10 KEY FINANCIALS OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2014)
FIG. 11 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 12 KEY FINANCIALS OF BIOMERIEUX BY APPLICATIONS (2013)
FIG. 13 KEY FINANCIALS OF BIOMERIEUX BY GEOGRAPHY (2013)
FIG. 14 SWOT ANALYSIS OF BIOMERIEUX
FIG. 15 KEY FINANCIALS OF HOLOGIC, INC. BY OPERATING SEGMENTS(2012)
FIG. 16 KEY FINANCIALS OF HOLOGIC, INC. BY GEOGRAPHY (2012)
FIG. 17 SWOT ANALYSIS OF HOLOGIC, INC.
FIG. 18 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY SEGMENT (2013)
FIG. 19 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY GEOGRAPHY (2013)
FIG. 20 SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
FIG. 21 KEY FINANCIALS OF CEPHEID INC. BY GEOGRAPHY(2013)
FIG. 22 KEY FINANCIALS OF CEPHEID INC. BY CLINICAL AND NON CLINICAL MARKET(2013)
FIG. 23 SWOT ANALYSIS OF CEPHEID INC.
FIG. 24 KEY FINANCIALS OF DANAHER CORPORATION BY OPERATING (SEGMENT) 2013
FIG. 25 KEY FINANCIALS OF DANAHER CORPORATION BY GEOGRAPHY (2013)
FIG. 26 SWOT ANALYSIS OF DANAHER CORPORATION
FIG. 27 KEY FINANCIALS OF AFFYMETRIX, INC. BY OPERATING SEGMENTS (2013)
FIG. 28 KEY FINANCIALS OF AFFYMETRIX, INC. BY GEOGRAPHY (2013)
FIG. 29 SWOT ANALYSIS OF AFFYMETRIX INC.
FIG. 30 KEY FINANCIALS OF ALERE INC. BY THERAPEUTICS (2013)
FIG. 31 KEY FINANCIALS OF ALERE INC. BY GEOGRAPHY (2013)
FIG. 32 SWOT ANALYSIS OF ALERE INC.
FIG. 33 KEY FINANCIALS OF ABBOTT LABORATORIES BY OPERATING SEGMENTS (2013)
FIG. 34 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 35 KEY FINANCIALS OF DIASORIN BY TECHNOLOGY (2013)
FIG. 36 KEY FINANCIALS OF DIASORIN BY GEOGRAPHY (2013)
FIG. 37 SWOT ANALYSIS OF DIASORIN
LIST OF TABLES
TABLE 1 GLOBAL SYPHILIS TESTING MARKET, MODERATE GROWTH SCENARIO, BY GEOGRAPHY, VALUE ($MILLION), 2020-2025
TABLE 2 GLOBAL SYPHILIS TESTING MARKET, MODERATE GROWTH SCENARIO, BY GEOGRAPHY, VOLUME (MILLION), 2020-2025
TABLE 3 GLOBAL SYPHILIS TESTING MARKET, RAPID GROWTH SCENARIO, BY GEOGRAPHY, VALUE ($MILLION), 2020-2025
TABLE 4 GLOBAL SYPHILIS TESTING MARKET, RAPID GROWTH SCENARIO, BY GEOGRAPHY, VOLUME (MILLION), 2020-2025
TABLE 5 GLOBAL SYPHILIS TESTING MARKET, DIMINISHING GROWTH SCENARIO, BY GEOGRAPHY, VALUE ($MILLION), 2020-2025
TABLE 6 GLOBAL SYPHILIS TESTING MARKET, DIMINISHING GROWTH SCENARIO, BY GEOGRAPHY, VOLUME (MILLION), 2020-2025
TABLE 7 SYPHILIS PREVENTIVE SERVICES BY CDC
TABLE 8 GLOBAL SYPHILIS TESTING MARKET VALUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 9 GLOBAL SYPHILIS TESTING MARKET VOLUME, BY GEOGRAPHY, 2014-2020 (MILLION)
TABLE 10 GLOBAL SYPHILIS TESTING MARKET BY TYPES, VALUE ($MILLION), 2014-2020
TABLE 11 GLOBAL SYPHILIS TESTING MARKET BY TYPES, VOLUME (MILLION), 2014-2020
TABLE 12 GLOBAL SYPHILIS TESTING MARKET, BY GEOGRAPHY, 2014-2020, VALUE ($MILLION)
TABLE 13 GLOBAL SYPHILIS TESTING MARKET, BY GEOGRAPHY, 2014-2020, VOLUME (MILLION)
TABLE 14 NORTH AMERICA SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
TABLE 15 NORTH AMERICA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
TABLE 16 U.S. SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 17 MEXICO SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 18 CANADA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 19 EUROPE SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
TABLE 20 EUROPE SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
TABLE 21 SPAIN SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 22 GREECE SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 23 BELGIUM SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 24 GERMANY SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 25 MOLDOVA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 26 UNITED KINGDOM SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 27 REST OF EUROPE SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 28 ASIA PACIFIC SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
TABLE 29 ASIA PACIFIC SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
TABLE 30 INDIA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 31 CHINA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 32 JAPAN SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 33 AUSTRALIA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 34 OTHERS ASIA PACIFIC SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 35 LAMEA SYPHILIS TESTING MARKET, VALUE, ($MILLION), 2014-2020
TABLE 36 LAMEA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
TABLE 37 LATIN AMERICA SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
TABLE 38 LATIN AMERICA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
TABLE 39 ARGENTINA SYPHILIS TESTING MARKET , VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 40 MIDDLE EAST SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
TABLE 41 AFRICA SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
TABLE 42 AFRICA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
TABLE 43 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 44 ROCHE DIAGNOSTICS OPERATING SEGMENTS
TABLE 45 BIOMERIEUX COMPANY SNAPSHOT
TABLE 46 BIOMERIEUX OPERATING SEGMENTS
TABLE 47 HOLOGIC, INC. COMPANY SNAPSHOT
TABLE 48 HOLOGIC, INC. OPERATING SEGMENTS
TABLE 49 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 50 BECTON DICKINSON AND COMPANY OPERATING SEGMENTS
TABLE 51 CEPHIDE INC COMPANY SNAPSHOT
TABLE 52 CEPHEID INC. OPERATING SEGMENTS
TABLE 53 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 54 DANAHER CORPORATION OPERATING SEGMENTS
TABLE 55 AFFYMETRIX INC. COMPANY SNAPSHOT
TABLE 56 AFFYMETRIX, INC. OPERATING SEGMENTS
TABLE 57 ALERE INC. COMPANY SNAPSHOT
TABLE 58 ALERE INC. OPERATING SEGMENTS
TABLE 59 ABBOTT LABORATORIES COMPANY SNAPSHOT
TABLE 60 ABBOTT LABORATORIES OPERATING SEGMENTS
TABLE 61 DIASORIN COMPANY SNAPSHOT
TABLE 62 DIASORIN OPERATING SEGMENTS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : November 2019
$ 3600
Published On : November 2019
$ 3600
Published On : November 2019
$ 3600
$ 3950
Published On : April 2019
$ 3000
